Peer-reviewed veterinary case report
Combined cytokine vaccine and gene therapy for canine sarcomas
By Finocchiaro, Liliana M E et al.·Published in Research in veterinary science·2011·Unidad de Transferencia Gené·View original on PubMed →
PetCaseFinder translated the abstract of this peer-reviewed paper into plain English so pet owners can read it. We do not publish original research — every detail traces back to the citation above. How we work →
Original publication title: Cytokine-enhanced vaccine and interferon-β plus suicide gene as combined therapy for spontaneous canine sarcomas.
- Species:
- dog
Plain-English summary
A group of dogs with soft tissue and bone tumors (sarcomas) received a new treatment combining a special vaccine and a gene therapy to help fight their cancer. This treatment was given either alone or after surgery and was found to be safe and well tolerated. In some dogs, the therapy led to complete or partial tumor shrinkage, and it helped prevent the cancer from coming back or spreading to other areas. Most importantly, many of the dogs lived for over a year with a good quality of life after starting this treatment.
People also search for: dog sarcoma treatment · canine cancer vaccine · soft tissue tumor in dogs · osteosarcoma therapy for dogs
Abstract
Eleven soft tissue- and five osteosarcoma canine patients were subjected to: (i) periodic subcutaneous injection of irradiated xenogeneic cells secreting hGM-CSF and hIL-2 mixed with allogeneic or autologous tumor homogenates; and (ii) injections of cIFN-β and HSVtk-carrying lipoplexes and ganciclovir, marginal (after surgery) and/or intratumoral (in the case of partial tumor resection, local relapse or small surface tumors). This treatment alone (4 patients) or as surgery adjuvant (12 patients), was safe and well tolerated. In those patients presenting local disease (6/11), the suicide gene plus cIFN-β treatment induced local antitumor activity evidenced by the objective responses (3 complete, 2 partial) and stable diseases (2). In addition, the treatment prevented or delayed local relapse, regional metastases (lymph nodes developed only in 3/16) and distant metastases (0/16), suggesting a strong systemic antitumor immunity. The most encouraging result was the long survival times of 10 patients (>1 year, with good quality of life).
Find similar cases for your pet
PetCaseFinder finds other peer-reviewed reports of pets with the same symptoms, plus a plain-English summary of what was tried across them.
Search related cases →Original publication on PubMed: https://pubmed.ncbi.nlm.nih.gov/21300385/